Treatment of Dural Arteriovenous Fistulas With SQUID™ Liquid Embolic Agent

CompletedOBSERVATIONAL
Enrollment

50

Participants

Timeline

Start Date

January 1, 2017

Primary Completion Date

July 30, 2020

Study Completion Date

August 29, 2020

Conditions
Dural Arteriovenous Fistula
Interventions
DEVICE

Squid

"SQUID™ is injected into the vascular site to be treated, under fluoroscopic control. DMSO dissipates in the blood and causes precipitation of EVOH in which the tantalum powder is trapped. It then forms a consistent spongy embolus.~This embolus solidifies from the outside inwardly while moving distally in the vessel. The non-adhesive character of the embolus allows slow and controlled injections while leaving in place the microcatheter."

Trial Locations (7)

12351

Klinische und interventionelle Neuroradiologie Vivantes Klinikum Neukölln, Berlin

13353

Charité-Universitätsmedizin Berlin, Berlin

45131

Alfried Krupp Krankenhaus Rüttenscheid, Essen

79106

Klinik für Neuroradiologie Universitätsklinikum Freiburg, Freiburg im Breisgau

81377

LMU Klinikum der Universität München, München

86156

Klnikum Augsburg, Augsburg

Unknown

University Clinic Bochum, Bochum

All Listed Sponsors
collaborator

University Hospital Schleswig-Holstein

OTHER

lead

Dr. Markus Alfred Möhlenbruch

OTHER

NCT03524976 - Treatment of Dural Arteriovenous Fistulas With SQUID™ Liquid Embolic Agent | Biotech Hunter | Biotech Hunter